Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group

Scandinavian Journal of Infectious Diseases
B BrismarC E Nord

Abstract

118 patients with complicated intra-abdominal infections participated in an open randomized comparative multicenter trial in order to compare the clinical and microbiological efficacy and safety of biapenem with imipenem/cilastatin (Tienam). 31 men and 27 women (mean age 52.3 years) were enrolled in the biapenem group, and 43 men and 17 women (mean age 52.3 years) in the imipenem/cilastatin group. The patients received either biapenem 500 mg every 8 h or imipenem/cilastatin 500 mg/500 mg every 6 h by intravenous infusion for up to 13 days (mean 6.5 days). 28/43 evaluable patients (65.1%) receiving biapenem and 27/40 evaluable patients (67.5%) in the imipenem/cilastatin group were clinically cured. The microbiological response was satisfactory in 28/43 evaluable patients (65.1%) receiving biapenem and in 27/40 evaluable patients (67.5%) receiving imipenem/cilastatin. No significant differences in clinical or microbiological efficacy between the two treatment groups were found. The present study shows that biapenem may be useful in the treatment of intra-abdominal infections.

References

Dec 1, 1992·Antimicrobial Agents and Chemotherapy·B BrismarT Skau
Aug 1, 1992·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C E NordI Persson
Nov 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J S SolomkinJ Bartlett
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·K UbukataS Mitsuhashi
Aug 1, 1990·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M Yoshida, S Mitsuhashi
Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Jan 1, 1995·The Journal of Antimicrobial Chemotherapy·B BrismarT Skau
Jul 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G S CooperR A Salata

❮ Previous
Next ❯

Citations

Jan 25, 2003·Surgical Infections·John E MazuskiUNKNOWN Therapeutic Agents Committee of the Surgical Infections Society
Mar 27, 2013·Antimicrobial Agents and Chemotherapy·Ellie J C GoldsteinC Vreni Merriam
Oct 17, 2002·Drugs·Caroline M Perry, Tim Ibbotson
Apr 20, 2014·The Journal of Antimicrobial Chemotherapy·Joan P CannonShellee A Grim
Apr 2, 2002·Expert Opinion on Investigational Drugs·Giovanni BonfiglioGiuseppe Nicoletti
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Ioannis P KioumisDavid P Nicolau
Apr 23, 2005·The Cochrane Database of Systematic Reviews·P F WongD J Leaper
Nov 2, 2014·The Annals of Pharmacotherapy·Kimberly A Toussaint, Jason C Gallagher
Dec 29, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xiuwen WuJianan Ren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
A M Clarke, S J Zemcov
© 2021 Meta ULC. All rights reserved